Biomimetic drug delivery platforms based on mesenchymal stem cells impregnated with light-responsive submicron sized carriers-Reference-Cited by-同舟云学术

Biomimetic drug delivery platforms based on mesenchymal stem cells impregnated with light-responsive submicron sized carriers

Published:2020 Issue:4 Volume:8 Page:1137-1147
ISSN:2047-4830
Container-title:Biomaterials Science
language:en
Short-container-title:Biomater. Sci.

Author:

Muslimov Albert R.¹²³⁴⁵,Timin Alexander S.¹²³⁶⁷^ORCID,Bichaykina Valery R.⁸⁹¹⁰¹¹,Peltek Oleksii O.⁸⁹¹⁰¹¹,Karpov Timofey E.¹²¹³³,Dubavik Aliaksei¹⁴¹⁵¹⁶¹¹,Nominé Alexandre⁸⁹¹⁰¹¹¹⁷,Ghanbaja Jaafar¹⁷¹⁸¹⁹²⁰,Sukhorukov Gleb B.⁶⁷²¹¹¹²²^ORCID,Zyuzin Mikhail V.⁸⁹¹⁰¹¹^ORCID

Affiliation:

1. First I. P. Pavlov State Medical University of St. Petersburg

2. Saint-Petersburg

3. Russian Federation

4. Nanobiotechnology Laboratory

5. St Petersburg Academic University

6. Research School of Chemical and Biomedical Engineering

7. National Research Tomsk Polytechnic University

8. Faculty of Physics and Engineering

9. ITMO University

10. St Petersburg

11. Russia

12. Peter the Great St Petersburg Polytechnic University

13. 195251 St Petersburg

14. Faculty of Photonics and Optical Information

15. Center of Information Optical Technologies ITMO University

16. 197101 St Petersburg

17. Jean Lamour

18. University of Lorraine/CNRS

19. Nancy

20. France

21. 634050 Tomsk

22. Skolkovo Institute of Science and Technology

Abstract

Synthetic organic and inorganic carriers often have limitations associated with problematic targeting ability or non-optimized pharmacokinetics, and, therefore, they have restricted therapeutic potential.

Funder

Russian Foundation for Basic Research

Russian Science Foundation

Ministère de l'Education Nationale, de l'Enseignement Superieur et de la Recherche

Publisher

Royal Society of Chemistry (RSC)

Subject

General Materials Science,Biomedical Engineering

Link

http://pubs.rsc.org/en/content/articlepdf/2020/BM/C9BM00926D

Reference50 articles.

1. Doxil® — The first FDA-approved nano-drug: Lessons learned